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Protease Inhibitors: A New 
Strategy Against HIV 
Weapon and a New 
Kenneth  D. Phil l ips,  PhD,  RN 
Until recently, reverse transcriptase inhibitors 
have been the mainstay for treating HIV 
infection. Now, three protease inhibitors have 
been approved. Early evidence suggests that 
triple therapy delays the progression of HIV 
infection. An understanding of these new drugs 
and treatment strategies is imperative for 
clinicians. This article (1) reviews HIV's 
structure and replication process, (2) discusses 
currently approved reverse transcriptase and 
protease inhibitors, (3) describes the 
antiretroviral drugs" modes of action, (4) 
discusses important nursing implications for 
monitoring clients on these drugs, and (5) 
presents current scientific evidence regarding the 
effectiveness of combination therapy strategies. 
Key words: Antiretroviral therapy, HIV/AIDS, 
protease inhibitors, reverse transcriptase 
inhibitors 
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A decade and a half after acquired immunodeficiency 
syndrome (AIDS) was first identified, this life-threaten- 
ing illness continues to elude a cure. Until recently, 
reverse transcriptase inhibitors have been the mainstay 
for treating HIV infection (Fischl et al., 1987; Weber, 1993; 
Yarchoan et al., 1986; Yarchoan et al., 1989). In 1995, a 
new classification of drugs, protease inhibitors, was 
added to the armamentarium for treating HIV infection. 
Although the data are limited, early evidence suggests 
that a combination of reverse transcriptase inhibitors and 
protease inhibitors delays the progression of HIV disease 
and prolongs the lives of H1V- infected people (Collier et 
al., 1996). Only one brief report regarding the use of pro- 
tease inhibitors in combination therapy to treat HIV 
infection was found in the nursing literature (New Wave, 
1996). The purpose of this paper is to review HIV's repli- 
cation process, discuss the different classifications of 
antiretroviral agents, describe anfiretroviral drugs' mode 
of action, and describe nursing implications for monitor- 
ing dients on these antiretroviral drugs. 
Replication of the Human Immunodefic iency Virus 
In order to understand how antiviral drugs work in 
combating HIV, it is important to understand the struc- 
ture and life cycle of the HW. 
Structure of the Human Immunodeficiency Virus 
HIV is the retrovirus responsible for AIDS (Barr6- 
Sinoussi  et al., 1983; Gallo & Wong-Staal ,  1985; 
Montagnier, 1985). Retroviruses contain their genetic 
material on two single strands of ribonucleic acid (RNA) 
rather than deoxyribonucleic acid (DNA). HIV consists 
of an envelope and a core (Figure 1). The outer envelope 
contains two important glycoproteins, gp120 and gp41. 
Glycoprotein 120 enables HIV to bind to T helper cells 
and other host cells that have a CD4+ receptor site on 
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Figure 1. Structure of the Human Immunodeficiency Virus 
Figure by Tammy Simpson, University of South Carolina, 
College of Nursing. Used with permission. 
their cell membranes,  and gp41 enables the viral enve- 
lope to fuse with the host cell membrane. The envelope 
is lined with a viral protein, p17. 
The core is surrounded by  a membrane that is made 
up  of three proteins, p24, p6, and p7. The core contains 
two strands of viral RNA and enzymes- - reverse  tran- 
scriptase, RNAse, polymerase,  integrase, and protease 
(Fauci, 1993; Gallo, 1987,1988; Greene, 1993; Haase, 1990). 
Table I summarizes the virus' main components. 
Life-Cycle of  the H u m a n  Immunodef i c i ency  Virus 
Figure 2 represents  HIV's  replicat ion process. The 
Roman numerals refer to the stages in HIV's replication 
process. HIV replication takes place inside host cells bear- 
ing a CD4+ marker. A brief summary  of the stages of 
H1V replication is presented to illustrate the point in the 
life cycle of HIV that antiretroviral drugs work. 
9 Stage I. Glycoprotein 120 binds to the CD4+ pro- 
tein on host cells. 
9 Stage II. Glycoprotein 41 facilitates fusion of the 
viral coat with the CD4+ cell membrane. 
9 Stage III. Once inside the cell, the virus undergoes 
an uncoating process and releases two single strands 
of RNA into the cytoplasm of the CD4+ cell. 
Table 1. Components of the Human Immunodeficiency Virus 
Protein Coded Location Function 
9 gp120 Coat glycoprotein Allows the HIV to bind 
to CD4+ receptor sites 
such as T helper cells. 
9 gp 41 Coat glycoprotein Allows the HIV enve- 
lope to fuse with the 
plasma membrane of a 
cell bearing a CD4+ 
receptor site. 
9 p17 Coat protein Becomes part of the 
outer coat of the new 
HIM. 
9 p24 Core protein Forms the core capsid, 
which surrounds the 
viral RNA and enzymes. 
9 p6 Core protein Becomes part of the 
nucleocapsid. 
9 p7 Core protein Becomes part of the 
nucleocapsid. 
9 Reverse Core enzyme Converts viral RNA to a 
transcriptase single strand of viral 
DNA. The strand of 
viral RNA and the 
newly formed viral 
DNA remain attached. 
9 RNAse Core enzyme Degrades the RNA tem- 
plate from the DNA, 
leaving a single strand 
of DNA. 
9 Polymerase Core enzyme Makes an exact copy of 
the single strand of 
DNA and causes the 
two strands of viral 
DNA to join. 
9 Integrase Core enzyme Inserts the newly 
formed double strand of 
viral DNA into the DNA 
of the host cell. 
9 Protease Core enzyme Cleaves the proteins of 
noninfectious, immature 
virions, thus making 
them infectious. 
Adapted from Gallo, 1987,1988; Greene, 1993; Haase, 1990 
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Figure by Tammy Simpson, University of South Carolina, College of Nursing. Used with permission. 
9 Stage IV. A single strand of DNA is copied from 
the RNA by the enzyme reverse transcriptase. 
Reverse transcriptase contains two other enzymes: 
RNAse and polymerase. RNAse is necessary to 
remove the RNA from the DNA copy. Then, poly- 
merase makes another exact copy of the viral DNA 
and causes the two strands of DNA to join. 
9 Stage V. The newly formed double strand of viral 
DNA moves into the nucleus of the host cell, 
where it is incorporated into the DNA of the host 
cell by the enzyme integrase. The host cell begins 
to make messenger RNA (mRNA). Then, mRNA 
moves from the host cell nucleus to the ribosomes, 
where it guides the production of viral proteins. 
Transfer RNA (tRNA) carries amino acids from the 
host cell cytoplasm to the ribosomes. 
9 Stage VI. In the ribosomes, the amino acids are 
assembled into large, inactive precursor proteins. 
9 Stage VII. During this stage, immature virions are 
released from the host cell through the process of 
budding. These virions, which are noninfectious, 
contain large precursor proteins that must be bro- 
ken into smaller glycoproteins,  proteins, and 
enzymes before they become infectious. 
9 Stage VIII. By the action of protease, these large 
precursor proteins are split into a variety of smaller 
glycoproteins, proteins, and enzymes that are 
essential for the virus to become a mature, infec- 
tious retrovirus. 
There are several points in the life cycle of HIV where 
a great deal of research has been directed at finding drug 
therapies for HIV infection. The research has been 
directed at preventing the: (1) binding of gp120 to the 
CD4+ receptor sites, (2) fusion of the viral coat with the 
cell membrane of the CD4+ receptor site, (3) uncoating of 
the virus once inside the host cell, (4) synthesis of viral 
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DNA from viral RNA by the action af reverse transcrip- 
tase, (5) degradation of viral RNA leaving it attached to 
the newly formed strand of viral DNA, (6) insertion of 
viral DNA into the host cell DNA by the integrase, (7) 
protein synthesis in the rough endoplasmic reticulum of 
the host cell, (8) budding,  and (9) maturat ion of the 
newly formed HIV by the action of protease (Johnston & 
Hoth, 1993; Weber, 1993). Presently, the greatest success 
in treating HW infection has been the use of reverse tran- 
scriptase inhibitors and protease inhibitors. Reverse tran- 
scriptase inhibitors work in Stage Ill by preventing tran- 
sc r ip t ion  of viral  RNA into  viral  DNA. Protease  
inhibitors work in Stage VIII by preventing the cleavage 
of precursor proteins into mature viral proteins. 
Classifications of Antiretroviral Drugs 
Reverse Transcriptase Inhibitors 
Reverse transcriptase inhibitors comprise the first major 
effective classification of antiretroviral drugs. Reverse tran- 
scriptase is an enzyme found in retroviruses that is neces- 
sary for their replication. The reverse transcriptase 
inhibitors have shown effectiveness in preventing infection 
of uninfected CD4+ cells (Fischl et al., 1987; Lambert et al., 
1990; Merigan et al., 1989; Yarchoan et al., 1989). They do 
not block viral production by CD4+ cells that are chroni- 
cally infected (Ashorn et al., 1990; Dreyer et al., 1989; 
Kempf et al., 1990; McQuade et al., 1990; Meek et al., 1990; 
Reedijk et al., 1995; Rich et al., 1990; Roberts et al., 1990). 
Nucleoside analogues, such as AZT, are substituted 
for natural substrates used to manufacture viral DNA. 
The growing chains of viral DNA are prematurely termi- 
nated,  thus prevent ing  viral replication. Since HIV 
mutates so rapidly (Martin, Redshaw, & Thomas, 1995), 
resistance of HW to reverse transcriptase inhibitors and 
other antiretroviral drugs frequently occurs early in the 
course  of t he rapy  and h inde r s  their  effect iveness  
(Boucher et al., 1992; Fitzgibbon et al., 1992; Larder, 
Darby, & Richman, 1989; Reichman et al., 1993). This 
problem can be reduced by using drug combinations. 
For example, lamivudine, which is not effective when 
used alone, slows development of resistance to zidovu- 
dine (Eron et al., 1995). Clients taking zidovudine plus 
larnivudine showed significant improvements in CD4+ 
counts and viral load (Eron et al.). Table 2 summarizes 
the nucleoside analogue reverse transcriptase inhibitors. 
Protease Inhibitors 
Proteases are enzymes that split the peptide bonds of 
larger proteins  into smaller proteins  (Roose & Van 
Noorden, 1995). HIV protease helps HIV mature (Kohl et 
al., 1988; Peng, Ho, Chang, & Chang, 1989; Tang, Lin, 
Hartsuck, & Lin, 1992). HIV protease is part of the precur- 
sor protein gp160 (Buegelski et al., 1994). HIV protease 
autocleaves itself from the precursor  protein gp160 
(Buegelski, Kirsh, & Hart, 1994). Following autodeavage, 
gpl60 is cleaved into the two glycoproteins of the viral coat 
(Decroly et al., 1994). Then, HIV protease promotes matu- 
ration of HIV by splitt~g retroviral precursor polyproteins 
into structurally essential glycoproteins and proteins 
(Krausslich & Wimmer, 1988; Robins & Plattner, 1993; 
T~sdale et al., 1995). Thus, HIV protease allows immature, 
noninfectious virions to become mature, infectious virions. 
Glycoprotein 160 is a polyprotein precursor that is 
encoded by the gag- pol region of the HIV genome. H1V 
protease splits gp160 into gp120 and gp41 (Decroly et al., 
1994). By chopping gp160 into its component parts, I-tW 
protease promotes binding (gp120) of the virus to the 
CD4+ receptor site and fusion (gp41) of the viral coat 
with the CD4+ cell membrane. There are eight possible 
cleavage sites on gp160. Nine ma tu re  proteins  are 
formed by the action of protease: (1) p17, (2) p24, (3) an 
unknown protein, (4) p7, (5) p6, (6) protease, (7) reverse 
transcriptase, (8) RNAse, and (9) integrase (Buegeiski et 
al., 1994; Debouck et al., 1987; Gelderblom et al., 1990). 
The proteins of HIV are summarized in Table 1. 
Protease inhibitors prevent  matura t ion  of newly 
formed virions by prevent ing the cleavage of HIV's 
polyproteins (Ashore et al., 1990; Kohl et al., 1988; Loeb, 
Hutchinson, Edgell, Farmerie, & Swanstrom, 1989; Tang 
et al., 1992). Thus, protease inhibitors prevent immature, 
noninfectious viruses from becoming mature, infectious 
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Table 2. Reverse Transcriptase Inhibitors 
Reverse Transcriptase Inhibitor Adult Dose Adverse Effects Nursing Implications 
9 Zidovudine 
(azidothymidine; AZT; ZDV) 




Monitor the client's complete 
blood count. 
Instruct client to report muscle 
pain and fatigue. 
9 Didanosine 
(dideoxyinosine; ddI) 
Body weight > 132 lbs: 200 mg 
orally q12h 





Since ddI is degraded in acid, 
tablets must be crushed, 
chewed, or dispersed in water 
to release the buffer or given 
with a buffered powder. 
Inform dient to report abdomi- 
nal pain, nausea, and vomiting. 
9 Zalcitabine 
(dideoxycytidine; ddC) 






Inform client to report abdomi- 
nal pain, nausea, and vomiting. 
Instruct client to monitor for 
signs of peripheral neuropathy. 
9 Stavudine (D4T) Body weight > 132 lbs: 40 mg 
orally q12h 






Instruct client to monitor for 
signs of peripheral neuropathy. 
Observe for indication of neu- 
tropenia. 




May be administered with or 
without food. 
Inform client to report abdomi- 
nal pain, nausea, and vomiting. 
Instruct client to monitor for 
signs of peripheral neuropathy. 
Adapted from Olin, B. (1996). Facts and comparisons. St. Louis: Lippincott. 
o n e s  (Debouck et al., 1987; Gott l inger ,  Sodroski ,  & 
Haseltine, 1989; Kohl et al., 1988; Tang et al., 1992). Many 
antiretroviral ly active protease inhibitors have been 
developed (Buegelski et al., 1994; Tk~ctale et al., 1995). The 
three protease inhibitors (saquinavir, ritonavir, and indi- 
navir) that have been approved by the Food and Drug 
Administration (FDA) are summarized in Table 3. 
S a q u i n a v i r .  Saquinavir  has been associated with  
significant increases in CD4+ cell counts and few side 
effects (Kitchen, Stewart, Bragman, & Weber, 1995). It 
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Table 3. Protease Inhibitors 
Protease Inhibitor Adult Dose Adverse Effects Nursing Implications 




Instruct client to take with a 
meal to increase absorption. 
Grapefruit juice may increase 
bioavaflability. 
Instruct client to avoid pro- 
longed exposure to direct sun- 
light until sensitivity to sun- 
light is known. 
9 Ritonavir 600 mg orally q12h Diarrhea 
Nausea 
Instruct client to take with 
food. 
Observe for elevations in 
serum triglycerides, AST, ALT, 
GGT, CPK, and uric acid. 
9 Indinavir 800 mg orally q8h Kidney stones 
Hyperbilirubinemia 
Avoid coadministration of 
nonsedating antihistamines, 
sedative hypnotics, or antiar- 
rhythmics (may be life- threat- 
ening). 
Instruct client not to take with 
meals; however, if gastric dis- 
tress occurs, take with a light 
snack. 
If didanosine is also pre- 
scribed, instruct client to take 
the two drugs one hour apart. 
Instruct client to increase oral 
fluid intake. 
Adapted from Olin, B. (1996). Facts and comparisons. St. Louis: Lippincott. 
is usua l ly  used  in combina t ion  wi th  ei ther  AZT or a 
n u c e l o s i d e  a n a l o g  (Davey,  G o l d s c h m i d t ,  & Sande ,  
1996). S a q u i n a v i r  is m o r e  e f fec t ive  in c o m b i n a t i o n  
wi th  AZT w h e n  the client has  not  t aken  AZT previ -  
ously. Since A Z T  has  been  w i de l y  p resc r ibed  in the 
HIV- infected cohort, some clinicians believe it may  be 
mos t  beneficial to combine saquinavir  wi th  either zal- 
citabine (ddC) or didanosine (ddI) (Davey et al., 1996). 
Ritonavir. Ritonavir has been associated with signifi- 
can t ly  i nc reased  CD4+ coun t s  ( D a n n e r  et al., 1995; 
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Kelleher, Carr, Zaunders, & Cooper, 1996; Markowitz et 
al., 1995), increased CD8+ counts (Kelleher et al.), 
increased responsiveness to new antigens as measured by 
phytohemagglutinin antigen [PHA] mitogen blastogene- 
sis (KeUeher et al.), increased responsiveness to previously 
encountered antigens (Kelleher et al.), and decreased viral 
load (Danner et al.; Kelleher et al.; Markowitz et al.). 
Following treatment with ritonavir, significant decreases 
in CD4+ cells bearing a CD38 receptor site following treat- 
ment with fitonavir have been observed (Kelleher et al.); 
this may be a very important finding, since an increase in 
these cells is associated with disease progression (Giorgi et 
al., 1994; Levacher et al., 1992). 
Indinavir. In clinical trials, dramatic reductions in 
viral load and improvements in CD4+ cell counts have 
been reported in clients receiving indinavir. In fact, used 
in combination with AZT and 3TC, viral loads have been 
reduced to undetectable levels (Davey et al., 1996). 
Triple Therapy: A New Strategy 
Protease inhibitors have shown effectiveness when 
used as a monotherapy (Danner et al., 1995; Kelleher et 
al., 1996; Markowitz et al., 1995; Massari et al., 1996). 
However, synergistic effects have been demonstrated 
when reverse transcriptase inhibitors and the protease 
inhibitors are combined (Collier et al., 1996; Kageyama et 
al., 1992). The term synergy identifies the concept that the 
beneficial effects of two or more drugs are greater when 
the drugs are combined than would be expected if either 
of the drugs was used alone. Synergistic effects have been 
noted when certain reverse transcriptase inhibitors are 
combined: (1) zidovudine [AZT] and lamivudine [3TC], 
(2) zidovudine [AZT] and didanosine [dbl.], and (3) 
zidovudine [AZT] and zalcitabine [ddC] (Merigan, 1995). 
HIV's ability to develop resistance to drugs is a major 
obstacle to effective treatment (Richman, 1993). The term 
resistance refers to the concept that a previously effective 
anfiretroviral drug becomes ineffective due to viral muta- 
tions. Viral mutations and subsequent resistance may be 
slowed by using a combination of drugs (Vella et al., 
1995). For instance, resistance of HIV to zidovudine may 
be delayed by combining zidovudine with a protease 
inhibitor (Schapiro, Winters, & Merigan, 1995) or lamivu- 
dine (Davey et al., 1996). In cross-resistance, development 
of resistance to one drug results in the development of 
resistance to other drugs of the same classification or 
other classifications. Cross-resistance is extremely prob- 
lematic in HIV infection. Resistance to one protease 
inhibitor may result in cross-resistance to other anfiretro- 
viral drugs, in particular other protease inhibitors (Chen 
et al., 1995; Condra et al., 1995). A mutation of only one 
genetic sequence results in cross- resistance to stavudine 
[d4T], didanosine [ddI], and dideoxycytidine [ddC] 
(Merigan, 1995). The term resistance- reversal connotes the 
concept  that the deve lopment  of resistance to one 
antiretroviral drug undoes the resistance that has devel- 
oped to another drug. An example of this is the pheno- 
typic resistance-reversal noted in the coadministration of 
z idovud ine  and lamivudine  (Boucher et al., 1993; 
Merigan; Staszewski, 1995). 
Saquinavir, plus zidovudine, plus dideoxycytidine. 
Phase II clinical trials indicate that combinations of 
saquinavir (SQV), zidovudine (ZDV), and dideoxycyti- 
dine (ddC) synergistically decrease H1V replication. In a 
study conducted by Collier et al. (1996), three treatment 
regimens were used: (1) saquinavir (SQV), plus zidovu- 
dine (ZDV), plus dideoxycytidine (ddC); (2) zidovudine 
(ZDV) plus dideoxycytidine (ddC); and (3) zidovudine 
(ZDV) plus saquinavir (SQV). Patients receiving a com- 
bination of saquinavir (SQV), plus zidovudine (ZDV), 
plus dideoxycytidine (ddC) demonstrated the greatest 
increase in CD4+ counts and the greatest decrease in 
viral load (Collier et al.). 
Ritonavir, plus zidovudine, plus zalcitabine. The 
effects of a six-month regimen of ritonavir, plus zidovu- 
dine, plus zalcitabine were studied in a group of 21 
patients (Abramowicz, 1996). Viral load decreased to 
undetectable levels in 5 of the 21 participants (Third 
Conference on Human Retroviruses and Opportunistic 
Infections, 1996) as reported in The Medical Letter on 
Drugs and Therapeutics. 
Indinavir, plus zidovudine, plus lamivudine. HIV 
viral load decreased to undetectable levels over a four 
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month  t reatment  per iod in 20 of 22 clients taking 
zidovudine (AZT), plus lamivudine (3TC), plus indi- 
navir. The participants in this s tudy had an average 
CD4+ cell count of 175 /mm 3 (Third Conference on 
Human  Retroviruses and Opportunist ic  Infections, 
1996) as reported in The Medical Letter on Drugs and 
Therapeutics (Abramowicz, 1996). In a separate study, a 
s i x - m o n t h  course  of indinavir ,  z i d o v u d i n e ,  and 
lamivudine lowered HIV viral load to undetectable 
levels in 11 of 19 patients. The 'participants were previ- 
ously untreated and had an average CD4+ lymphocyte 
count of 150 cells/mm 3 (Third Conference on Human 
Retroviruses and Opportunistic Infections, 1996) as 
r e p o r t e d  in The Medical Letter on Drugs and 
Therapeutics. 
Nursing Implications 
Nurses use a holistic approach in the prescription and 
administration of medications. Administering antiretro- 
viral drugs requires special attention to all stages of the 
nursing process. 
Assessment 
A complete assessment should be performed prior 
to prescribing or administering any medication. When 
administering antiretroviral drugs, nurses need to be 
especially careful to determine the patient's allergies 
to medications (name of medication and type of reac- 
tion) and assess past  oppor tunis t ic  infections and 
malignancies. 
Nucleoside analogues. Data from a complete blood 
count, lymphocyte subset enumeration, and a chemical 
profile should be available prior to administering a 
nucleoside analogue. Six assessments must  be per- 
formed before administering a nucleoside analogue: 
First, ensure that the patient does not have anemia 
(hemoglob in  < 9.5 g / d l )  or g r a n u l o c y t o p e n i a  (< 
1000/mm3). If either is present, special precautions are 
needed when administering zidovudine. Second, check 
for elevated serum creatinine, which could make the 
pat ient  more prone to drug  toxicity. Third, assess 
patients for a history of pancreatitis, symptoms of pan- 
creatitis (i.e., abdominal pain, nausea, and vomiting), 
risk factors for pancreatitis (i.e., cholelithiasis and 
ethanol abuse), and elevations in either serum amylase 
or se rum lipase, which may  indicate pancreati t is .  
Pancreatitis is a potentially lethal side effect of nucleo- 
side analogues. Fourth, assess for early signs of periph- 
eral neuropathy (i.e., intermittent numbness, tingling, 
or pain in hands or feet). Fifth, perform a complete 
nutritional assessment (i.e., height, weight, serum albu- 
min, serum transferrin, serum prealbumin, and a 24- 
hour diet recall). Sixth, if the client is female, assess her 
pregnancy status. Zidovudine has been shown to be 
effective in preventing the vertical transmission of HIV 
from the mother to the fetus without harming the fetus 
when administered after the first 14 weeks of preg- 
nancy. However, drugs other than zidovudine have not 
been as thoroughly  tested in pregnancy. The other 
nucleoside analogues should be given during preg- 
nancy only when the benefits clearly outweigh the 
risks. See Table 2. 
Protease inhibitors..No major toxicities have been 
o b s e r v e d  as a resul t  of taking ei ther  of the three  
approved protease inhibitors. However, coadministra- 
tion of ritonavir and non-sedating antihistamines, seda- 
tive hypnotics, or antiarrhythmics may produce life- threat- 
ening situations such as oversedation, respiratory an~t,  or 
cardiac arrest (see Table 4, Abramowicz, 1996; Olin, 1996). 
Coadministration of these drugs with protease inhibitors 
other than ritonavir has led to s'nnilar life- threatening reac- 
tions. Always identify all the drugs the client is taking 
before prescribing or administering ritonavir. 
Plan 
During the planning phase, measurable goals are 
mutually established between the client and the nurse. In 
addition, the nurse makes a thorough assessment of all 
the patient 's drugs, including over- the-counter  and 
street drugs. In addition to the drug, route, dosage, and 
frequency, the nurse must know whether the client is 
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Table 4. Examples of Nonsedating Antihistamines, Sedative Hypnotics, and Antiarrhythmics* 
Nonsedating Antihistamines Sedative Hypnotics Antiarrhythmics Miscellaneous 
Astemizole 
Terfenadine 
Alprazolam Amiodarone Bupropion 
Clorazepate Bepridil Cisapfide 
Diazepam Encainide Clozapine 
Estazolam Flecainide Meperidine 
Flurazepam Propafenone Piroxicam 
Midazolam Quire'dine Propoxyphene 
Triazolam Rifabufin 
Zolpidem 
Adapted from Olin, B. (1996). Facts and comparisons. St. Louis: Lippincott. 
* Not an indusive list 
able to take the medication independently. If not, does 
he or she have adequate social support  to help with 
taking the medications? Does the client have adequate 
resources for obtaining the drug (i.e., money, insur- 
ance, transportation)? Since it is never enough to sim- 
ply say, "Take your  medic ine ,"  nurses  mus t  plan 
methods for teaching the client about the medicines, 
and must make themselves available to answer ques- 
tions that arise after the client leaves the office. For 
instance, the client may ask, "It is my birthday. Can I 
have a glass of wine with my medications?" Nurses 
can help the client find a way  to procure  the pre- 
scribed medications and to incorporate these medica- 
tions into his or her life. Be familiar with industry, 
social, or governmental compassionate drug programs 
for indigent patients. 
Implementation 
Clients should be taught the name, dosage, route, and 
frequency of any drug being prescribed. Apprise the 
client of possible side effects and any special precautions 
that must  be taken while taking a part icular drug.  
Provide written instructions in addition to verbal ones. 
Inform the client that current drugs are not a cure and 
will not prevent the transmission of HIV. Table 5 outlines 
additional client instructions. 
Ev~uat ion 
Evaluation is an ongoing process and is performed at 
every contact with the client. Assess for past or present 
opportunistic infections or malignancies. A complete 
blood count should be drawn at frequent intervals and 
the results evaluated. If the client develops anemia or 
granulocytopenia, a drug may need to be withdrawn, 
the dosage changed, or another drug such as epoietin 
alfa recombinant or granulocyte colony stimulating fac- 
tor added. Liver, pancreatic, and renal values also should 
be assessed at regular intervals. 
Evaluation of antiretroviral therapy is based on viral 
markers. Three viral markers have been more significant 
than others in monitoring disease progression and treat- 
ment effectiveness: CD4+ cell counts, p24 antigenemia, 
and viral load. 
CD4+ cell counts. The normal CD4+ cell count ranges 
f rom 589 to 1505 cells/~tl (Fischbach,  1996). T 
helper/inducer cells (CD4+) are invaded and destroyed 
by HIV. So a decline in CD4+ cells generally signifies dis- 
ease progression (Flaskerud & Ungvarski, 1995) and 
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Table 5. Client Instructions 
Instruct client to: 
Recognize and report the signs and symptoms of periph- 
eral neuropathy fi.e., numbness, tingling, or pain in the 
hands and feet). 
2. Recognize and report the signs and symptoms of acute 
pancreatitis (i.e., abdominal pain., nausea, or vomiting). 
3. Recognize and report early signs and symptoms of anemia 
(i.e., shortness of breath, increased weakness, tiredness, 
fatigue, lightheadedness, dizziness, or palpitations). 
4. Drink 2-3 liters of fluids per da3a 
5. Report signs of opportunistic infections in the mouth (i.e., 
furry tongue, mouth lesion, or thrush), in the vagina (i.e., 
itching, burning, redness, or discharge), or in the rectum 
(i.e, itching, drainage). 
6. Avoid nonprescription medications unless approved by a 
healthcare provider. 
7. Take drugs as scheduled to maintain an appropriate blood 
level of the drug. 
8. Avoid drug "holidays" (periods when the drug is not 
taken), which may allow the development of resistant 
strains of HIM 
9. Take saquinavir, ritonavir with food. 
10. Take didanosine, indinavir, or zalcitabine on an empty 
stomach. 




Chew, crush, or disperse didanosine in water before swal- 
lowing to release the buffer or to take it with a buffered 
powder. 
Understand that the long- term side effects of these drugs 
remain unknown. 
14. Take prophylactic drugs to prevent opportunistic infec- 
tions and malignancies. 
15. Use contraceptives to prevent pregnancy while taking 
antiretroviral drugs (remind the client that effective barrier 
methods are needed to prevent the transmission of HW). 
indicates that the treatment strategy should be re- exam- 
ined (Davey et al., 1996). 
CD4+ cells can be destroyed by four processes: (1) 
binding of gp120 can lead to preprogrammed cell death 
known as apoptosis; (2) binding of gp120 can terminate 
cell division known as anergy; (3) gp120 on the surface of 
virions budding from the surface of an infected CD4+ cell 
can bind to CD4+ receptors on other CD4+ cells, causing 
them to tear; or (4) multiple CD4+ cells clump together in 
a process known as syncytium formation, resulting in the 
death of many CD4+ cells at one time (Peterson, 1995). 
Antiretroviral treatment has been reserved for a CD4+ 
cell count less than 500 ceUg/n'lIn 3. Therapy should be initi- 
ated in clients who have a progressive dedine of CD4+ cells 
to 500 cells/mm 3 or in clients with a CD4+ cell count greater 
than 500 cells/ram 3, if their CD4+ cells are rapidly declining 
(Davey et al., 1996). Undoubtedl)4 new recommendations 
be forthcoming regarding combination therapy. 
The CD4+ cell count is an indirect marker  of HIV 
replication. Therefore, the cell count may rise in response 
to an infection other than HIV or decline transiently in 
response to stimuli other than increased viral replication 
(Davey et al., 1996; Harrigan, 1995; Merigan, 1995). This 
limits the significance of the CD4+ cell count in tracking 
the progression of the disease or the effectiveness of ther- 
apy. In fact, it remains  controversial  whe ther  CD4+ 
counts have utility in predicting disease progression or 
survival (Choi, Lagakos, Schoole)~ & Volberding, 1993). 
However, in general, a significant reduction of the CD4+ 
cell count suggests that the treatment strategy needs to 
be re-examined and that the treatment plan may need to 
be changed (Davey et al., 1996). 
p24 ant igenemia .  An o t h e r  test  tha t  is used  as a 
marker of disease progression is the p24 antigen test. The 
p24 antigen is one of the core proteins. Early after infec- 
tion antibodies to p24 appear. In the p24 antigen test, a 
spectrophotometer is used to measure the optical density 
that develops when  p24 antigen in a patient 's  serum 
complexes with recombinant p24 antibody and is sub- 
jected to the enzyme linked anti-p24 ELISA test. The 
greater the optical density, the greater the concentration 
of p24 antigen in the patient's serum. Antibody forma- 
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tion is one of the major problems associated with this 
reliability of this test. In vivo, the HIV-infected person 
makes antibodies to p24 in his or her serum. These anti- 
bodies attach to the p24 in the serum. In v/tro, the recom- 
binant antibodies are unable to attach to the p24 antigen 
unless the serum is treated with an acid wash. This acid 
wash procedure releases the attachment of the p24 anti- 
gen- antibody complex, but it decreases the reliability of 
this test. Therefore, its usefulness as a marker of disease 
progression is limited (Piliero & Libman, 1996). 
The p24 antigen test provides diagnostic information 
in infants born to HIV-infected mothers. In the early 
months after delivery, maternal antibodies to HIV and 
other maternal antibodies persist in the infant. The infant 
with antibodies to HIV may or may not be HIV- infected. 
The presence of p24 antigen in the serum of the new 
born allows early diagnosis and treatment of HIV infec- 
tion (Cooper & Pelton, 1996). 
Viral load. Viral load is a significant step in treating 
HIV infection. HVA RNA levels have greater power to 
predict disease progression than CD4+ cell count alone 
(O'Brien et al., 1996). Since viral load is a direct marker of 
viral replication, it does not rise and fall in relationship to 
the white blood cell count. However, HIV viral load can 
transiently increase in the presence of illnesses such as 
pneumonia or influenza (Sax & Flory, 1996). Viral load 
measures the presence of viral RNA in the plasma, but 
not in other tissues (Davey et al., 1996). 
Four methods are currently used to measure viral 
load: (1) quantitative competitive polymerase chain reac- 
tion [PCR], (2) nucleic acid sequence-based amplification 
[NASBA], (3) branched- chain DNA [b-DNA], and (4) 
the amplicor microwell plate assay (Harrigan, 1995). 
In the early, asymptomatic stage of HIV infection, viral 
load may be about 5,000 virions/ml (Merigan, 1995). It rises 
as the disease progresses and declines in response to effec- 
tive anfiretroviral therapy (Davey et al., 1996). In advanced 
stages of HIV infection, viral load may be as much as I mil- 
lion virions/ml (Merigan). A rise in viral load indicates 
increased viral replication. A reduction in viral load greater 
than 0.5 log10 following initiation of treatment indicates that 
the antiretroviral therapy is effective (Davey et al., 1996). If a 
dienYs viral load fails to drop or does not drop by 0.5 log10 
following treatment, the approach should be re-evaluated, 
and the care plan may need to be modified (Davey et al., 
1996). Viral load determinations are recommended at base- 
line, prior to beginning antiretroviral therapj6 and approxi- 
mately one month after beginning or changing antiretrovi- 
ral therapy (Sax & Flory, 1996). Table 6 summarizes the 
interpretation of HIV viral load testing. 
Special Considerations 
Clients should be advised to avoid "drug holidays" 
(periods of time when drugs are not taken). Drug holi- 
days permit activation of viral replication and increase 
the risk of mutation and the development of resistant 
strains. Resistance to one protease inhibitor may be con- 
ferred on other protease inhibitors and thus limit future 
treatment options. 
Avoid coadministration of nonsedating antihistamines, 
sedative hypnotics, or anfiarrhythmics. When these drugs 
are administered with the protease inhibitors, life threaten- 
ing or lethal complications may arise (Olin, 1996). Examples 
of each of the nonsedating antihistamines, sedative hyp- 
notics, and antiarrhythmics are provided in Table 4. 
Avoid coadministration of antiretroviral drugs with 
similar adverse effects (Merigan, 1995). For instance, 
avoid  s imu l t aneous  use  of d idanos ine  [ddI] and 
dideoxycytidine [ddC], because acute pancreatitis and 
peripheral neuropathy are adverse reactions of both 
drugs (Davey et al., 1996; Merigan). 
Nurses approach every aspect of patient care holisti- 
cally, including the prescription and administration of 
medications. Quite often, nurses work more closely with 
the client than other clinicians. The nurse's responsibility 
goes far beyond prescription and administration of a 
medication. Nurses help people find resources to pro- 
cure medications, teach them the effects and side effects 
of their medications, teach them how to take their medi- 
cation to obtain maximum benefit, and help them find 
ways to incorporate drug therapies into their lives. When 
an informed decision is made by the client to discontinue 
antiretroviral therapy, the nurse supports the client. 
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Table 6. Interpretation of H1V RNA V'tral Load 
Viral Load Clinical Significance of Results 
< 10,000 copies per mm 3 Low risk of disease progression 
10,000 to 100,000 copies per mm 3 Moderate risk of disease progression 
> 100,000 copies per mm 3 High risk of disease progression 
Adapted from Sax, P., & Flory, J. (1996). Information for patients: Viral load testing. AIDS Clinical Care, 8, p. 31 
D i s c u s s i o n  
P r o t e a s e  i n h i b i t o r s  a n d  t r ip le  t h e r a p y  p r o v i d e  a 
n e w  level of  h o p e  in the search for  an  effective treat- 
m e n t  for  HIV infect ion ( W l o d a w e r  & Erickson,  1993). 
H o w e v e r ,  the  a d v e n t  of  H I V  pro tease  inh ib i tors  pre-  
sents  n e w  research  ques t ions .  W h i c h  c o m b i n a t i o n  of  
d rugs  is best  for  a par t icu lar  g r o u p  of  clients? At  w h a t  
poin t  shou ld  a client be  s tar ted on  a par t icular  combi-  
na t ion  of d rugs?  
A l t h o u g h  s lower  than  that  of  z i dovud i ne ,  deve lop-  
m e n t  of  resistance to HIV protease  inhibi tors  has  been  
noted (Markowitz et al., 1995; Martin et al., 1995; T~sdale 
et al., 1995). This resistance reminds  us that the search for 
definitive prevent ion and  t reatment  mus t  continue. The 
progress m a d e  wi th  triple therapy  is ve ry  encouraging.  
Strategies for treating HIV infection are rapidly  increas- 
ing. Nurses,  especially advanced  practice nurses provid-  
ing care for HIV-infected individuals,  m u s t  keep current 
wi th  n e w  medica t ions  that  are be ing  released. Existing 
d r u g s ,  n e w  d r u g s ,  c o m b i n a t i o n s  o f  t hose  d rugs ,  a n d  
direct  m e a s u r e m e n t  of  R N A  viral load will  a l low indi- 
vidualization of treatment strategies. 
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